Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon α-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for 16 or 24 weeks
2009 ◽
Vol 29
(2)
◽
pp. 237-241
◽
Keyword(s):
2012 ◽
Vol 19
(9)
◽
pp. 623-634
◽
Keyword(s):
2009 ◽
Vol 3
(3)
◽
pp. 468-479
◽
Keyword(s):
2010 ◽
Vol 18
(4)
◽
pp. 245-251
◽
2013 ◽
Vol 48
(7)
◽
pp. 839-847
◽
Keyword(s):
Keyword(s):
2010 ◽
Vol 139
(4)
◽
pp. 1267-1276.e4
◽